Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Pharma News Only (pfe,mrk,wla, sgp, ahp, bmy, lly) -- Ignore unavailable to you. Want to Upgrade?

To: runningelk who wrote (1650)	2/26/2000 1:28:00 PM
From: Rob Loney	Read Replies (1) \| Respond to of 1722

I can't believe the buying opportunity for BMY right now! I work in sales for a competing pharmaceutical company, and all of my customers are drooling at the prospect of the soon to be launched Omapatrilat. I've been told by investigators in double-blinded trials, that "you can't blind me to the effect of this drug". It's that much better at lowering blood pressure than anything else available. This drug has multiple mechanisms, and has the ability to dramatically increase NO synthesis (the key to protection against the complications of Coronary Artery Disease). Studies to further demonstrate it's superiority will be presented at the American college of Cardiology Meeting in Anaheim, March 10-16. Look for a run up at this point, or even sooner if the FDA "Fast- Tracked" approval comes through sooner than the early April expectation. Omapatrilat, which has completed late stage phase 3 studies, will be the "Lipitor" of blood-pressure lowering. (If you're not aware, Lipitor does $4 billion yearly in North America). In my opinion, the lay people who are out chasing the biotech sector, and buying anything with the word "gene" in it have completely lost it.

To: runningelk who wrote (1650)	2/26/2000 9:54:00 PM
From: Laurens	Respond to of 1722

Well,have a good look at NBIX. At least some serious investors are betting on their armamentarium - it went from 6 to 33 in less than a year,and everytime there is a (small) sell off, it comes back and moves to new highs. The SI thread information is excellent and shows serious research

To: runningelk who wrote (1650)	3/6/2000 11:55:00 AM
From: Valley Girl	Read Replies (1) \| Respond to of 1722

I also have AMGN though it's been a bit disappointing, also on a valuation basis it's kinda steep compared to other similar big-cap biotechs. I eschew stocks that have more hype than earnings, so in general that leaves me on the sidelines for biotech. However, I also own BGEN and MEDI, both of which have rather attractive-looking earnings forecasts relative to their prices (for MEDI don't look at the backward P/E, look at the earnings estimates for 2000 and 2001). My one old-line pharma, MRK, has really been beaten down in this market, now trading at 20x next year's earnings. Perhaps the market knows something I don't. To Zeren's question I believe the main reason the pharmas are down is election-year uncertainty over government involvement in prescription drugs. I'll take a look at BMY; looks like the legal system took a bite out of Taxoi. Valuation computations, source for EPS data Zack's: Fwd EPS EPS 5yr% Fair Analysts Stock Price P/E P/E 2000 2001 grow P/E Ratings ================================================================ MRK 57 23 21 2.78 3.07 12% 30 2.20 Buy BMY 46 25 20 2.34 2.65 13% 31 2.00 Buy AMGN 65 134 60 1.08 1.29 17% 37 1.92 Buy BGEN 117 79 66 1.80 2.15 24% 50 2.00 Buy MEDI 205 255 108 1.88 2.81 47% 117 1.27 Strong Buy